35th week of 2009 patent applcation highlights part 35 |
Patent application number | Title | Published |
20090214392 | Nano-fluidic Trapping Device for Surface-Enhanced Raman Spectroscopy - A nano-fluidic trapping device and method of fabrication are disclosed. In one embodiment, a nano-fluidic trapping device for assembling a SERS-active cluster includes a substrate. The nano-fluidic trapping device further includes a SERS-active cluster compartment. The SERS-active cluster is formed in the SERS-active cluster compartment. In addition, the nano-fluidic trapping device includes a reservoir. The reservoir allows introduction of target molecules into the nano-fluidic trapping device. Moreover, the nano-fluidic trapping device includes a microchannel. The microchannel allows the target molecules to be introduced to the SERS-active cluster compartment from the reservoir. The nano-fluidic trapping device also includes a nanochannel. The SERS-active cluster compartment, the reservoir, the microchannel, and the nanochannel are disposed within the substrate. | 2009-08-27 |
20090214393 | Method of generating an oxygen-enriched gas for a user - A method of generating an oxygen-enriched gas for a user via an oxygen generating system is disclosed herein. The oxygen generating system includes at least one sieve bed having a nitrogen-adsorption material disposed therein, the nitrogen-adsorption material being configured to adsorb nitrogen from a feed gas introduced thereto, thereby generating the oxygen-enriched gas therefrom. The at least one sieve bed has an internal gas pressure within a volume defined by the at least one sieve bed. The method includes measuring the internal sieve bed pressure, measuring an ambient atmospheric parameter, and detecting inhalation of the user. The method further includes selectively controlling, substantially in real time, delivery of the oxygen-enriched gas to the user based on at least one of the internal sieve bed gas pressure measurement, the ambient atmospheric parameter measurement, the inhalation detection, or combinations thereof. | 2009-08-27 |
20090214394 | CENTER FEED SYSTEM - The present invention features a center feed system for use within a delayed coking system, or any other similar system. The center feed system features an inlet sleeve which slidably engages a retractable nozzle, with inlet and outlet, in fluid connection with a feed source of residual byproduct, allowing residual byproduct to flow from the feed source into the interior of a vessel, thus effectuating or inducing even thermal distribution throughout the vessel. | 2009-08-27 |
20090214395 | Raw Material Efficiency Method and Process - A method and apparatus are disclosed for controlling product discharge from a fluidized bed reactor and for minimizing the loss of the unreacted monomer in the fluidizing gas upon removing the solid polymer product from the reactor. The method and apparatus utilize at least one detector in the product tank or its vent line and a control system in communication with the detector and the product tank fill valve, along with certain algorithms, to adjust by an iterative process, the product discharge time, thereby maximizing resin fill in the product tank and minimizing the lost reactor gas volume. | 2009-08-27 |
20090214396 | Engine Exhaust Catalysts Containing Palladium-Gold - An emission control catalyst that exhibits improved CO and HC reduction performance includes a supported platinum-based catalyst, and a supported palladium-gold catalyst. The two catalysts are coated onto different layers, zones, or monoliths of the substrate for the emission control catalyst such that the platinum-based catalyst encounters the exhaust stream before the palladium-gold catalyst. Zeolite may be added to the emission control catalyst as a hydrocarbon absorbing component to boost the oxidation activity of the palladium-gold catalyst. | 2009-08-27 |
20090214397 | Exhaust Gas Treatment Apparatus - An exhaust gas treatment apparatus includes a device (A) which is provided in an exhaust system and which selectively reduces NO | 2009-08-27 |
20090214398 | WASTE LIQUID PROCESSING DEVICE - A waste liquid processing device includes: a waste liquid tank to which a liquid to be hardened by radiation of an energy ray is introduced as a waste liquid; a radiation unit which radiates the energy ray for hardening the waste liquid to the waste liquid introduced to the waste liquid tank; and a buffer tank which temporarily stores the waste liquid in a non-hardened state between a waste liquid discharging source and the waste liquid tank and which intermittently introduces the stored waste liquid to the waste liquid tank. | 2009-08-27 |
20090214399 | VACUUM PROCESSING APPARATUS - The invention provides a vacuum processing apparatus for processing a sample placed within a processing chamber in a vacuum reactor using plasma generated within the processing chamber, the apparatus comprising an atmospheric transfer chamber disposed on a front portion of the apparatus for transferring the sample under atmospheric pressure, a vacuum transfer chamber arranged on a rear side of the atmospheric transfer chamber for transferring the sample in the inner side of the chamber being vacuumed, a lock chamber disposed between and connecting the vacuum transfer chamber and the atmospheric transfer chamber, a plurality of vacuum processing units including vacuum reactors and arranged in the circumference of and connected to the vacuum transfer chamber, and a plurality of flow controllers arranged in a space below the vacuum transfer chamber or the lock chamber for controlling flow rates of a plurality of gases for processing the sample to be supplied respectively to the vacuum processing units. | 2009-08-27 |
20090214400 | PLASMA PROCESSING APPARATUS - Provided is a plasma processing apparatus capable of generating a uniform plasma by preventing a nonuniformity of a current flow in a slot antenna. A dielectric plate is disposed to close a top opening of a plate cover and a slot antenna for generating plasma is disposed on the dielectric plate. By allowing an outer periphery of the slot antenna to make direct contact with an inner wall portion of the plate cover by using a conductive member having elasticity, when a microwave is supplied to slot antenna, it is possible to make an electrical resistance between the inner wall portion of the processing vessel and the outer periphery of the flat plate antenna substantially the same at any point in the entire circumference of the processing vessel, so that magnitude of the microwave current flowing in the slot antenna can be made approximately the same. | 2009-08-27 |
20090214401 | PLASMA PROCESSING METHOD - The invention provides a plasma processing method capable of reducing particle caused by flinging up of particles by airflow due to the pressure fluctuation in the processing chamber during the time the sample is carried into the processing chamber, subjected to plasma processing and carried out of the processing chamber. The invention provides a plasma processing method using a plasma processing apparatus comprising multiple plasma processing chambers for processing samples, a transfer chamber connected to the processing chambers for transferring samples, and a supply system for supplying gas which is the same gas as a transferring gas supplied to the transfer chamber to both the processing chambers and transfer chamber or to only the processing chambers, wherein the process comprises (b) a step of transferring the sample into the processing chamber with the transferring gas supplied to the processing chamber; (c) thereafter, generating plasma from the transferring gas supplied to the processing chamber while maintaining the supply of transferring gas to the processing chamber; (d) a step of switching the gas supplied to the processing chamber from transferring gas to processing gas while maintaining plasma by supplying processing gas continuously to the processing chamber; and (e) a step of subjecting the sample to plasma processing. | 2009-08-27 |
20090214402 | Microplasma Array - The invention relates to a microplasma array for producing low-temperature plasmas at or close to atmospheric pressure. According to the invention, the walls of holes which are introduced into a substrate ( | 2009-08-27 |
20090214403 | SEPARATOR AND UNLOADING DEVICE - An unloading device includes: a separator connected to a suction hose connected to the reactor and to another suction hose connected to a vacuum car, the separator separating a catalyst sucked from the reactor by the vacuum car from air; a flexible container bag for storing the catalyst dropped from the separator; and a dumping hose provided between the separator and the flexible container bag for transferring the catalyst dropped from the separator to the flexible container bag. The separator includes a blower unit for blowing a gas to the catalyst unloaded in the separator body toward a lower cone and a cover that openably closes a catalyst outlet. | 2009-08-27 |
20090214404 | Process and Apparatus for Improved Methods for Making Vinyl Acetate Monomer (VAM) - The invention provides methods, apparatus and chemical systems for making vinyl acetate from ethylene, oxygen, and acetic acid. | 2009-08-27 |
20090214405 | Bubble Column Reactor and Operation Method Thereof - The present invention relates to a bubble column reactor comprising a column reactor having a sparger plate dividing the column reactor into a top reaction compartment and a bottom compartment, characterized in that an inlet and outlet line for introducing and disposing a flushing medium are connected to the bottom compartment; and an operation method thereof. | 2009-08-27 |
20090214406 | CATALYTIC CONVERTER WITH IMPROVED START-UP BEHAVIOUR - In automotive exhaust gas catalysts with a metallic honeycomb composed of corrugated and smooth sheet layers, it is known that the heat capacity and thermal conductivity of the honeycomb can be reduced by perforations in the sheet layers. As a result, the honeycomb heats up more rapidly and the catalytic coating applied on the honeycomb reaches its operating temperature more rapidly. A disadvantage here is the reduction in the support surface area by the perforations in the sheet layers. According to the invention, suitable adjustment of the properties of the coating suspension used for the catalytic coating and of the dimensions of the holes relative to one another allows the holes to be filled permanently with catalyst material. The resulting catalyst has, at the same coating concentration as a catalyst with unperforated sheet layers, a significantly reduced heat capacity and thermal conductivity. | 2009-08-27 |
20090214407 | Separation of carbon dioxide from nitrogen utilizing zeolitic imidazolate framework materials - The present invention relates to the selective separation of carbon dioxide (“CO | 2009-08-27 |
20090214408 | PREPARATION AND USE OF CATIONIC HALIDES, SEQUESTRATION OF CARBON DIOXIDE - A process is described for sequestering carbon dioxide. In the process, a carbonate, oxide or hydroxide of a divalent cation is reacted with the carbon dioxide and water and/or with a species resulting from the dissolution of the carbon dioxide in water, to form a hydrogen carbonate of the divalent cation. The carbonate, oxide or hydroxide of the divalent cation has a low solubility in water. The divalent cation of the hydrogen carbonate of the divalent cation thus formed is exchanged for a monovalent cation using an ion exchange medium, to produce a solution of a hydrogen carbonate of the monovalent cation. | 2009-08-27 |
20090214409 | Process for production of a borohydride compound - A process for production of a borohydride compound. The process comprises combining a compound comprising boron and oxygen with an adduct of alane. | 2009-08-27 |
20090214410 | SPLIT FLOW CONTACTOR - Systems and methods for contacting a liquid, gas, and/or a multi-phase mixture with particulate solids. The system can include a body having a first head and a second head disposed thereon. Two or more discrete fixed beds can be disposed across a cross-section of the body. One or more unobstructed fluid flow paths can bypass each fixed bed, and one or more baffles can be disposed between the fixed beds. | 2009-08-27 |
20090214411 | METHOD OF SELECTIVELY ELIMINATING METALLIC CARBON NANOTUBES, SEMICONDUCTING CARBON NANOTUBES AND PREPARATION METHOD THEREOF USING THE SAME - Metallic carbon nanotubes (“CNTs”) may be selectively eliminated and semiconducting CNTs may be prepared using light-irradiation. The light provided by the light-irradiation may have a wavelength of about 180 nm to about 11 μm. Further, the light may have an intensity of about 30 mW/cm | 2009-08-27 |
20090214412 | PROCESS FOR PRODUCING CARBON MATERIAL AND ALKALI ACTIVATION APPARATUS - Provided is a production process for a carbon material comprising an alkali activation reaction step in which a carbon precursor containing an activator selected from alkali metal compounds is heated under flow of inert gas. The above alkali activation reaction is carried out while allowing carbon dioxide gas to flow into a downstream part of an alkali activation reaction region on the condition that the carbon dioxide gas is not substantially brought into contact with the carbon precursor and the activator. This makes it possible to carry out alkali activation treatment safely and stably and obtain a carbon material useful for producing an electric double layer capacitor electrode having a high electrostatic capacity. | 2009-08-27 |
20090214413 | ORDERED MESOPOROUS CARBONS AND METHOD FOR MANUFACTURING SAME - The present invention relates to an ordered mesoporous carbon and method for manufacturing the ordered mesoporous carbon which is made from a surfactant, a carbon precursor, water (possibly mixed with an acid) and a water immiscible oil. In addition, the present invention relates to a method of formulating a composition which is used to manufacture the ordered mesoporous carbon. Moreover, the present invention relates to an activated carbon which is made by partially oxidizing an ordered mesoporous carbon. | 2009-08-27 |
20090214414 | PRODUCTION OF LITHIUM COMPOUNDS DIRECTLY FROM LITHIUM CONTAINING BRINES - Methods and apparatus for the production of low sodium lithium carbonate and lithium chloride from a brine concentrated to about 6.0 wt % lithium are disclosed. Methods and apparatus for direct recovery of technical grade lithium chloride from the concentrated brine are also disclosed. | 2009-08-27 |
20090214415 | System for generating oxygen using heat recycled from engine exhaust - A system for optimizing the quality of a vehicle's inner air includes an oxygen generator and an optimizer. The oxygen generator generates oxygen by dissociating water using recycled heat from the vehicle's exhaust. The optimizer automatically adjusts oxygen amount added into the vehicle's inner air according to the user's settings through an interface. | 2009-08-27 |
20090214416 | PROCESS FOR PREPARING A METAL HYDROXIDE - The invention provides a process for preparing a metal hydroxide comprising the steps of: (a) providing particles of a metal silicate; (b) mixing the particles with a mineral acid solution to obtain a slurry which comprises precipitated silica; (c) separating the precipitated silica from the slurry to obtain a remaining solution; (d) increasing the pH of the remaining solution to such an extent that a metal hydroxide is formed; (e) separating the metal hydroxide so obtained from the remaining solution; and (f) adding to the remaining solution obtained in step (e) an acid solution, thereby forming a salt containing solution, or (g) removing at least part of the base added in step (d) from the remaining solution obtained in step (e), thereby forming a salt containing solution. | 2009-08-27 |
20090214417 | PREPARATION OF COBALT-BORON ALLOY CATALYSTS USEFUL FOR GENERATING HYDROGEN FROM BOROHYDRIDES - A method of making a cobalt-boron alloy includes contacting an aqueous suspension of an oxide of cobalt, particularly a highly crystalline cobalt oxide, with a borohydride such as sodium borohydride. The resulting alloy may be used as a catalyst to produce gaseous hydrogen by hydrolysis of aqueous sodium borohydride. | 2009-08-27 |
20090214418 | MOLECULAR SIEVE SSZ-83 - The present invention is directed to a new crystalline molecular sieve designated SSZ-83 synthesized using a 1,4-bis(N-butylpiperidinium)butane dication or a 1,4-bis(N-butylpyrrolidinium)butane dication as a structure directing agent. | 2009-08-27 |
20090214419 | SELF-ASSEMBLED BIODEGRADABLE POLYMERSOMES - The invention concerns a block copolymer of polyethylene oxide and polycaprolactone, the polyethylene oxide having a number average molecular weight from about 2.0 to about 3.8 kD, the block copolymer having a fraction of polyethylene oxide of from about 11.8 to 18.8 percent by weight. The invention also concerns polymersomes made from such copolymers and to methods of making the polymersomes. | 2009-08-27 |
20090214420 | Method of Diagnosis and Treatment and Agents Useful for Same - The present invention relates generally to a method of screening for the level of neoplastic cell death in a subject. More particularly, the present invention provides a method of screening for the level of neoplastic cell death by detecting the level of expression of telomerase protein and/or gene by dead cells in said subject or in a biological sample derived from said subject. The method of the present invention is useful in a range of applications including, but not limited to, assessing a neoplastic condition, monitoring the progression of such a condition, assessing the effectiveness of a therapeutic agent or therapeutic regime and predicting the likelihood of a subject either progressing to a more advanced disease state or entering a remissive state. The present invention also provides diagnostic agents useful for detecting telomerase protein and/or nucleic acid molecules. | 2009-08-27 |
20090214421 | ANTIBODY DIRECTED AGAINST PAP2a AND USE THEREOF FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES - The present invention aims at developing a gene delivery system which has a high selectivity to a target cell and can introduce and express a gene with high efficiency, particularly developing such a system for use in a gene delivery therapy using a viral vector. The present invention provides a method for targeting a drug, which comprises the step of delivering a drug containing a therapeutic gene to a target site using an anti-PAP2a antibody. | 2009-08-27 |
20090214422 | DNA encoding a novel RG1 polypeptide - The present invention relates to novel human extracellular matrix polypeptides, designated RG1, polynucleotides encoding the polypeptides, methods for producing the polypeptides, expression vectors and genetically engineered host cells for expression of the polypeptides. The invention further relates to antibodies directed against the polypeptides and to methods for using the polynucleotides, and polypeptides, and antibodies in research, diagnosis, and therapeutic applications. | 2009-08-27 |
20090214423 | SELECTIVE TARGETING OF TUMOR VASCULATURE USING RADIOLABELLED ANTIBODY MOLECULES - A specific binding member that binds human ED-B, wherein the specific binding member is labelled with an isotope selected from the group consisting of | 2009-08-27 |
20090214424 | Human glycoprotein hormone superagonists and uses thereof - The present invention provides improved methods of imaging, targeted therapy and detection and diagnostics using modified glycoprotein hormones having increased activity over wild-type hormones. | 2009-08-27 |
20090214425 | TUMOR THERAPY WITH REPLICATION COMPETENT SINDBIS VIRAL VECTORS - Disclosed herein are methods for treating a mammal harboring a solid tumor which expresses higher levels of High Affinity Laminin Receptors (LAMR) than normal cells of the same lineage comprising systematically administering to a mammal in need of such treatment a therapeutically effective amount of a Replication Competent (RC) Sindbis virus vector, wherein said vector encodes a suicide gene. | 2009-08-27 |
20090214426 | Assay Method - The present invention is related to the field of pharmacy. The present invention more particularly discloses a method of determining the emotional, sensory, physiological, social and cognitive effects of a pain condition in a non human animal and further discloses a method for preclinically identifying pharmaceutical therapeutics which improve the emotional, sensory, physiological, social and cognitive effects associated with a pain condition in a non human animal. | 2009-08-27 |
20090214427 | Novel peptides - Isolated peptides comprising an amino acid sequence having Formula I | 2009-08-27 |
20090214428 | Human Monoclonal Antibodies Against Hendra and Nipah Viruses - The present invention relates to monoclonal antibodies that bind or neutralize Hendra or Nipah virus. The invention provides such antibodies, fragments of such antibodies retaining Hendra or Nipah virus-binding ability, fully human antibodies retaining Hendra or Nipah virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention. | 2009-08-27 |
20090214429 | METHODS AND COMPOSITIONS RELATED TO TARGETING TUMORS AND WOUNDS - Disclosed are compositions and methods useful for targeting tumors, sites of injury and blood clots. The compositions and methods are based on peptide sequences that selectively bind to and home to tumors, sites of injury and blood clots in animals. The disclosed targeting is useful for delivering therapeutic and detectable agents to tumors, sites of injury and blood clots. | 2009-08-27 |
20090214430 | POLYPEPTIDE SPECIFICALLY BOUND TO PHOSPHATIDYLSERINE AND THE USE THEREOF - The present invention relates to a polypeptide specifically bound to phosphatidylserine and use thereof, and more particularly to a polypeptide having an amino acid sequence designated as sequence number 1 and specifically bound to phosphatidylserine, a phosphatidylserine detecting composition containing the polypeptide as an active ingredient, a detecting method of phosphatidylserine by using polypeptide, a apoptotic cell detecting containing the polypeptide as an active ingredient, a drug delivery composition containing the polypeptide as an active ingredient, a composition for treatment and prevention of a tumorous disease, and a composition for visualization of a tumorous region. A polypeptide having an amino acid sequence designated sequence number 1 is specifically bound to phosphatidylserine. Therefore, the polypeptide of the present invention is useful for detecting phosphatidylserine, furthermore detecting apoptotic cells expressing phosphatidylserine on the surface of the cell and tumor cells, and also useful for visualization of apoptotic cells or tumor cells. | 2009-08-27 |
20090214431 | IDENTIFICATION OF ERGOTHIONEINE TRANSPORTER AND THERAPEUTIC USES THEREOF - The transporter that translocates ergothioneine has been identified. Described are methods for identifying and obtaining compounds capable of modulating ergothioneine transport as well as the use of such compounds for the treatment of diseases ergothioneine may be involved in such as autoimmune diseases, in particular rheumatoid arthritis, as well as other diseases arising from cell damage caused by radiation, radicals and relative oxidant species. Furthermore, diagnostic means and methods for determining the presence or susceptibility to such a disease are provided. | 2009-08-27 |
20090214432 | Radicals and Their Use As Paramagnetic Agents in a DNP Process - The invention relates to new radicals, their use as paramagnetic agents in a method for the dynamic nuclear polarisation and a method for the dynamic nuclear polarisation of compounds comprising carboxyl groups. | 2009-08-27 |
20090214433 | HYPERPOLARIZED SOLID MATERIALS WITH LONG SPIN RELAXATION TIMES FOR USE AS IMAGING AGENTS IN MAGNETIC RESONANCE IMAGING - An imaging agent is disclosed for use in nuclear magnetic resonance imaging. The imaging agent includes a first substance and a second substance. The first substance includes at least one atom having non-zero nuclear spin providing a polarized magnetic orientation. The second substance is bound to the first substance and inhibits physical contact between the at least one atom and other atoms and molecules to thereby inhibit spin relaxation of the polarized magnetic orientation of the at least one atom. | 2009-08-27 |
20090214434 | METHOD OF DETECTING AND TREATING ALLOGENIC CELLS RESPONSIBLE FOR ENDOMETRIOSIS - There are presently provided methods for identifying an ectopic allogenic cell in a mammalian host, the methods comprising obtaining a first internal soft tissue image, administering an effective amount of iodine to potentiate the host's immune response to aberrant ectopic tissue, obtaining one or more subsequent internal soft tissue images after said administration and comparing the first internal soft tissue image and the one or more subsequent internal images to identify the ectopic allogenic cell. The methods can also be used for determining or improving the efficiency of treatment of pathology disease or disorder caused by the presence of allogenic commensal or commensal-like cells. Furthermore, the methods can be used to diagnose, and also treat, endometriosis. | 2009-08-27 |
20090214435 | Recombinant vector expressing MDR1 shRNA and thymidine kinase and use thereof - A recombinant vector capable of expressing MDR1 shRNA and thymidine kinase, and a use thereof. More specifically, provided is a recombinant vector capable of efficiently expressing MDR1 shRNA and thymidine kinase in a host cell, a transfectant cell comprising the same recombinant vector, a composition for treating neoplastic diseases, comprising the same recombinant vector, and a method for imaging of neoplastic lesions using the same recombinant vector. The recombinant vector of the present invention is capable of achieving efficient intracellular expression of MDR1 shRNA and a thymidine kinase-GFP fusion protein within the host cell and is therefore highly effective for combined therapy of anticancer drugs. Further, the recombinant vector of the present invention enables imaging of neoplastic lesions. Therefore, the recombinant vector of the present invention can be used in combination with other anticancer drugs for treatment of neoplastic diseases. | 2009-08-27 |
20090214436 | DICHROMIC FLUORESCENT COMPOUNDS - The present invention provides dichromic fluorescent compounds, as well as processes for making and methods for using the dichromic fluorescent compounds. | 2009-08-27 |
20090214437 | In Vivo Mitochondrial Labeling Using Positively-Charged Nitroxide Enhanced and Gadolinium Chelate Enhanced Magnetic Resonance Imaging - A system and method for acquiring MR imaging data from a subject includes administering positively-charged nitroxides or gadolinium chelates for in vivo mitochondrial labeling, acquiring MR imaging data from the subject, and reconstructing an image of the subject having enhanced contrast in areas including metabolic and/or mitotic activity. | 2009-08-27 |
20090214438 | METHODS AND COMPOSITIONS FOR THE PREPARATION AND USE OF TOXIN CONJUGATES - The present invention relates to methods for the preparation of toxin conjugates that are useful in vaccination and other therapies and diagnostics. In particular, methods are provided that involve a [3+2] cycloaddition between a first reactive unsaturated group on a toxin moiety and a second reactive unsaturated group on a bioactive moiety. Also provided are conjugates that are formed through this conjugation method, pharmaceutical compositions comprising these conjugates, and methods of using these pharmaceutical compositions for the treatment or diagnostic of antigen-related conditions, including tumors and infections. | 2009-08-27 |
20090214439 | Fluorinated Carbohydrates and Their Use in Tumor Visualization, Tissue Engineering, and Cancer Chemotherapy - The present invention relates to fluorine-containing monosaccharides that are useful for forming extracellular fluorinated glycoconjugates. Methods of forming extracellular fluorinated glycoconjugates comprise the steps of contacting a cell with a fluorine-containing monosaccharide, and incubating the cell under conditions whereby the cell internalizes the fluorine-containing monosaccharide, or a derivative thereof, on the surface of the cell. The present invention also relates to the use of a fluorine-containing monosaccharide in cellular imaging using fluorine NMR. The invention additionally relates to the use of fluorine containing monosaccharides in the treatment of cancer and inflammatory disease. | 2009-08-27 |
20090214440 | Method and device for examining a biological tissue - The invention relates to a method and a device for analyzing a biological tissue, whereby a luminescence light of a luminescence substance is detected. The aim of the invention is to increase the precision and reliability of the analysis. To this end, a permutation symmetry imbalance is generated in the tissue by a magnetic field, the permutation symmetry imbalance is modified at a pre-determined location by a magnetic alternating field, and the luminescence light is detected according to the pre-determined location. | 2009-08-27 |
20090214441 | Lipophilic Chelates and Their Use in Imaging - The invention relates to chelate compounds which can be used in MRI, the chelates being intended to be conveyed by lipophilic transporters, such as lipid nanoparticles or liposomes. The invention also relates to compounds comprising, in association, these chelates and these transporters, if appropriate connected via chemical bonding groups, and to their use in diagnostic imaging, it being possible for this association additionally to comprise biological targeting markers, denoted biovectors. | 2009-08-27 |
20090214442 | Oral Transmucosal Nicotine Dosage Form - Described herein are oral transmucosal solid dosage forms useful in treating nicotine addiction or as a nicotine substitute or replacement. By virtue of the formulation in combination with nicotine, the dosage forms transmucosally delivers an effective amount of nicotine to the recipient while permitting the accomplishing of such, and manufacture of such, using a relatively small, convenient and orally comfortable dosage form (e.g., tablet) size. | 2009-08-27 |
20090214443 | METHOD FOR RETARDING SYSTEMIC DELIVERY RATE FOR EASILY ABSORBABLE ACTIVE AGENTS - Drugs such as hormones, which are easily absorbable through the stratum corneum into the vascular network, are administered to the skin of a patient in an absorption retarding matrix material, thereby retarding the rate at which the drug penetrates into and through the skin. | 2009-08-27 |
20090214444 | POLY AROMATIC SODIUM CHANNEL BLOCKERS - Polyaromatic sodium channel blockers represented by the formula: | 2009-08-27 |
20090214445 | DELIVERY SYSTEMS FOR MANAGING RELEASE OF FUNCTIONAL INGREDIENTS IN AN EDIBLE COMPOSITION - A delivery system for inclusion in an edible composition is formulated to have at least one ingredient encapsulated with an encapsulating material. The delivery system and the resulting edible composition may include other ingredients to create a desired release profile for the at least one ingredient. | 2009-08-27 |
20090214446 | CYCLODEXTRIN INCLUSION COMPLEXES AND METHODS OF PREPARING SAME - Cyclodextrin inclusion complexes, guest stabilizing systems, and methods for preparing and using the same. Some embodiments of the present invention provide a method for making a guest stabilizing system. The method can include mixing cyclodextrin, a solvent and a guest to form a cyclodextrin inclusion complex. The method can further include adding uncomplexed cyclodextrin to the cyclodextrin inclusion complex to form a guest stabilizing system. Some embodiments of the present invention provide a method for making a beverage that can include mixing uncomplexed cyclodextrin, a guest and a solvent to form a beverage. | 2009-08-27 |
20090214447 | Preparation of cationic nanoparticles and personal care compositions comprising said nanoparticles - The present invention is directed to cationic nanoparticles, methods to make them, and the use of compositions containing said nanoparticles in personal care compositions or formulations. The nanoparticles are useful in personal care applications and impart antimicrobial properties to home and personal care products containing them. These cationic nanoparticles also contribute useful conditioning properties to hair-care and skin-care products. | 2009-08-27 |
20090214448 | Structures and Compositions Increasing The Stability of Peroxide Actives - A tooth whitening system is provided. The tooth whitening system includes a carrier, first and second substrates, and first and second tooth whitening compositions. | 2009-08-27 |
20090214449 | Preparation of precipitated silicas useful as fillers in silicon matrices - Carboxylic acids are employed during the preparation of precipitated silica or a suspension of precipitated silica to provide precipitated silicas with low water uptake, which are useful, for example, as reinforcing fillers for silicon matrices. | 2009-08-27 |
20090214450 | ORAL TREATMENT COMPOSITIONS AND RELATED METHODS OF MANUFACTURE - An oral treatment composition that includes a carrier, an active agent and a silicon dioxide compound. The active agent can be a variety of compositions, such as dental whitening or bleaching agents, desensitizing agents, antimicrobials, anti-plaque agents, remineralizing agents, anti-tartar agents, mouth fresheners, and anesthetics. Optionally, a processing aid can be added to the composition to streamline manufacture of the gel. The composition can be formed as a bead in a dental tray so that when a user applies the dental tray to their dental arch, the bead readily spreads over the surfaces of the teeth without the user having to supply significant force to achieve such spreading. | 2009-08-27 |
20090214451 | Oral Hygiene Compositions - Oral hygiene compositions suitable for use as dentifrice compositions comprising a silicon abrasive agent are provided. | 2009-08-27 |
20090214452 | Arginine Heteromers for Topical Administration - The invention is directed to a strategy for providing therapeutic or cosmetic benefit to skin by topically applying arginine chemically bound to a second (non-oligo arginine) compound in order to increase transepithelial delivery of arginine through a combination of increased solubility and flux across the skin. The arginine heteromers of the invention can add other complementary or beneficial properties for the skin beyond those that are arginine-related. | 2009-08-27 |
20090214453 | Use of Transmission Dyes for Protecting Human Skin From Browning and Ageing - Disclosed is the use of an aqueous dispersion comprising (a) a micronized sparingly soluble organic compound which has a UV-Vis spectrum with a maximum from 380 to 420 nm; and (b) an anionic dispersing agent for protecting the human skin from browning and skin aging. | 2009-08-27 |
20090214454 | METHOD FOR SKIN WHITENING USING (2Z, 8Z) - MATRICARIA ACID METHYL ESTER - The present invention relates to a method for inhibiting melanin generation or a method for skin whitening using an active fraction of | 2009-08-27 |
20090214455 | PROCESS FOR MAKING UP OR CARING FOR KERATIN MATERIALS, COMPRISING THE APPLICATION OF COMPOUNDS A AND B, AT LEAST ONE OF WHICH IS SILICONE-BASED - The invention relates to a cosmetic process for coating keratin materials, which consists in applying to the said keratin materials at least one compound A and at least one compound B, at least one of the compounds A and B being a silicone compound, the said compounds A and B being capable of reacting together via a hydrosilylation reaction, a condensation reaction, or crosslinking reaction in the presence of a peroxide. | 2009-08-27 |
20090214456 | Pigment Dispersion Composition Comprising and Ester Blend and Manufacture Thereof - A composition comprising a pigment dispersed in a liquid ester blend vehicle is disclosed, wherein the amount of pigment dispersed in the vehicle is substantially greater than previous pigment dispersions and the dispersion has improved flow properties to facilitate incorporation into a cosmetic formulation. The ester blend contains tridecyl trimellitate blended with dipentaerythritol hexacaprylate, tridecyl stearate and neopentyl glycol dicaprylate. | 2009-08-27 |
20090214457 | Antiperspirant Composition Based on Dicarboxylic Acid Diesters of a C6-C18 Dicarboxylic Acid With C12-C22 Fatty Alcohols - A composition for cosmetic compositions which contains (a) at least one dicarboxylic acid diester of a C6-C13 dicarboxylic acid with a C12-22 fatty alcohol; (b) at least one oil component. The composition provides excellent antiperspirant and deodorant sticks when combined with an antiperspirant or deodorizing composition. Addition of a pigment provides cosmetic sticks such as lipsticks. The composition can be water free. | 2009-08-27 |
20090214458 | COSMETIC COMPOSITION COMPRISING AT LEAST ONE SPECIFIC SILICONE COPOLYMER, AT LEAST ONE VOLATILE SOLVENT AND AT LEAST ONE CERTAIN SILICONE RESIN - The present disclosure relates to a keratin fiber treatment composition comprising at least one copolymer comprising at least one silicone resin and at least one fluid silicone, at least one volatile solvent, and at least one silicone resin having at least one trifunctional unit of the formula (R)SiO | 2009-08-27 |
20090214459 | METHOD OF USING CERTAIN CATIONIC POLYMERS AS ANTIOXIDANTS OR FREE-RADICAL SCAVENGERS - A method for providing a free-radical scavenging and/or antioxidant effect. | 2009-08-27 |
20090214460 | Composition Comprising a Monomer Compound Exhibiting an Optical Property, Method Making Use of Said Composition, a Monomer Compound and a Polymer Containing Said Monomer Compound and the Use Thereof - The invention relates to a cosmetic or pharmaceutical composition comprising, in a physiologically acceptable medium, at least one type of polymer containing at least one type of novel monomer compound exhibiting optical properties. Said invention also relates to a cosmetic method for making up or treating keratinous materials, in particular a body or face skin, lips, nails, eyebrows, eyelashes and/or hairs, including the application of said cosmetic composition to said materials. Novel monomer compounds exhibiting optical properties, polymers containing said compounds and the use thereof in a composition in order to transfer the optical properties thereto, in particular fluorescent or optical brightener properties are also disclosed. | 2009-08-27 |
20090214461 | Polymer particle dispersion, cosmetic composition comprising it and cosmetic process using it - The present disclosure relates to a cosmetic composition comprising, in a cosmetically acceptable medium, at least one dispersion of polymer particles in a liquid silicone medium, the polymer being a copolymer comprising at least one first block that is soluble and at least one second block that is insoluble in the silicone medium. | 2009-08-27 |
20090214462 | COCKCROACH JELLY BAIT - The present invention provides jelly bait for carrying insecticide to kill cockroaches. The jelly bait benefits from maintaining its softness for longer periods of time, which results in higher successful rates in luring and then killing cockroaches. The jelly bait can be injected with a syringe into the crevices or cockroach habitats for best effects in eradication of cockroaches. | 2009-08-27 |
20090214463 | Latent phase viral interleukin-10-(VII-10) and uses thereof - The present invention relates to a purified nucleic acid sequence encoding a homologue of human interleukin 10 (IL-10), wherein said IL-10 homologue is expressed during the latent phase of infection by a virus of the herpesvirideae group. The present invention also relates to uses of this polypeptide, in particular for diagnosing disease states and screening for modulator and inhibitor compounds of such polypeptides and in turn the virus itself, screening for infection in vertebrates and biological tissue, cleansing of infected biological tissues, and in the treatment and/or prophylaxis and/or diagnosis of disease caused by a virus of the herpesvirideae group. | 2009-08-27 |
20090214464 | COMPOUNDS FOR FLAVIVIRIDAE TREATMENT - Disclosed are non-immunosuppressive cyclophilin-binding cyclosporins, e.g. of formula I, Ia or II as defined herein, having useful properties in the prevention or treatment of Flaviviridae infections and Flaviviridae induced disorders. | 2009-08-27 |
20090214465 | Quinoxaline Derivatives as Antitumor Agents - The invention relates to methods of screening for binding partners, especially binding partners essential for the biological activity of erastin (e.g. VDACs such as VDAC3). The invention also provides reagents and methods for effective killing of cancer cells with erastin and related compounds or derivatives. | 2009-08-27 |
20090214466 | Methods of Alleviating Disorders and Their Associated Pain - The invention relates generally to the field of treatment of headache, post-laminectomy syndrome, and other disorders associated with localized pain. The compositions and methods described herein are useful for alleviating both the disorders and the pain associated therewith. | 2009-08-27 |
20090214467 | METHODS OF PROTECTING AGAINST APOPTOSIS USING LIPOPEPTIDES - The use of lipopeptides as inducers of NF-κB for the protection of mammals from the effects of apoptosis is described. | 2009-08-27 |
20090214468 | Localized Insulin Delivery for Bone Healing - A method of promoting bone healing in a non-diabetic patient in need thereof by locally administering a therapeutically effective amount of insulin to the patient. A drug delivery device, which includes insulin and a pharmaceutically acceptable carrier, wherein the device is adapted for localized administration of insulin to a patient in need thereof is also presented. | 2009-08-27 |
20090214469 | Methods and Compositions for the Treatment of Sepsis - Methods for the treatment of sepsis are disclosed. | 2009-08-27 |
20090214470 | EYE-DROP VACCINE CONTAINING COPOLYMER 1 FOR THERAPEUTIC IMMUNIZATION - The invention provides an eye-drop vaccine for therapeutic immunization of a mammal comprising Copolymer 1, a Copolymer 1-related peptide, or a Copolymer 1-related polypeptide, for treating neuronal degeneration caused by an injury or disease, disorder or condition in the central nervous system (CNS) or peripheral nervous system (PNS), for preventing or inhibiting neuronal secondary degeneration which may otherwise follow primary injury in the CNS, for promoting nerve regeneration in the CNS or in the PNS after an injury, disease, disorder or condition or for protecting CNS and PNS cells from glutamate toxicity. | 2009-08-27 |
20090214471 | USE OF PEGYLATED IL-10 TO TREAT CANCER - Provided are methods of treatment for tumors. In particular, methods are provided for use of a chemically modified IL-10 to treat tumors. | 2009-08-27 |
20090214472 | Interferon-beta polymer conjugates - Biologically-active, interferon-beta 1b-polymer conjugate compositions are disclosed. The polymer portion is preferably a polyalkylene oxide polymer having a molecular weight of at least about 12 kDa. Methods of making and using the same are also disclosed. | 2009-08-27 |
20090214473 | COMBINATION CHAPERONIN 10 AND BETA-INTERFERON THERAPY FOR MULTIPLE SCLEROSIS - A method of treating multiple sclerosis (MS) is provided which includes the step of administering a pharmaceutically-effective amount of chaperonin 10 and IFN-beta. Also provided are pharmaceutical compositions and a kit for treating MS, which include chaperonin 10 and IFN-beta. | 2009-08-27 |
20090214474 | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development - The present invention relates to prevention of congenital deformations. The invention further relates to cancer inhibition and prevention. The invention further relates to methods and compositions to modulate, antagonize, or agonize disparate signaling pathways that may converge to regulate patterning events and gene expression during prenatal development, post-natal development, and during development in the adult organism. | 2009-08-27 |
20090214475 | Extractability and Bioavailability of the Natural Antioxidant Astaxanthin From a Green Alga, Haematococcus Pluvialis - As the richest source of astaxanthin, a natural antioxidant and coloring agent, the unicellular green alga, | 2009-08-27 |
20090214476 | Novel mannose-specific adhesins and their use - The present invention relates to novel mannose-specific adhesins, and variants thereof, as well as nucleic acid sequences encoding these. The invention also relates to host cells expressing nucleic acids encoding the mannose-specific adhesins or variants thereof, as well as to pharmaceutical or nutraceutical compositions comprising the mannose-specific adhesins and/or host cells expressing the adhesins, and their use in treating or preventing bacterial infection. Further, screening methods suitable for identifying bacteria strains with probiotic properties are provided. | 2009-08-27 |
20090214477 | Human Marker Genes and Agents for Diagnosis, Treatment and Prophylaxis of Cardiovascular Disorders and Artherosclerosis - The invention relates to novel targets in the screening for compounds useful in the treatment and/or prophylaxis of a disease selected from the group comprising cardiovascular diseases, disorders of lipid metabolism or atherosclerosis. The invention relates to novel compounds for use as a medicament for diseases or conditions involving a disease selected from the group comprising cardiovascular diseases, disorders of lipid metabolism or atherosclerosis. The invention especially relates to antagonists and expression-inhibitory compounds that target G-protein coupled receptors (GPCRs), kinases and proteases, and to methods for identifying such compounds. The invention further relates to methods for identifying these antagonists and expression-inhibitory compounds, and methods for diagnosing a disease selected from the group comprising cardiovascular diseases, disorders of lipid metabolism or atherosclerosis or a susceptibility to such a condition. | 2009-08-27 |
20090214478 | Method of treating ocular diseases by gene therapy - A method for the treatment of diseases associated with mutations in ABCA4 gene by administering, to a subject in need thereof, an adeno-associated viral vector encoding an ABCR protein; genetic constructs and adeno-associated viral vectors for use in this method. | 2009-08-27 |
20090214479 | ATTENUATED REOVIRUS - Compositions and methods are provided that relate to an attenuated reovirus exhibiting oncolytic activity toward cancer cells while displaying reduced lytic activity toward non-malignant cells. Exemplified is an attenuated human reovirus derived from persistently infected fibrosarcoma cells that lacks wild-type reovirus S1 and S4 genes and consequently lacks a detectable reoviral outer capsid σ1 protein and expresses a mutated reoviral outer capsid σ3 protein. | 2009-08-27 |
20090214480 | Novel cancer antigen peptide and the use thereof - Novel peptides useful as a therapeutic and/or prophylactic agent of cancers, as well as medical uses thereof, are described. Each of these peptides have a consecutive amino acid sequence within a specific region of YKL-40 antigen expressing on the cell surface of brain tumor cells, that is, within the region aa10-19, aa49-61, aa74-83, aa96-117, aa152-161, aa177-185, aa202-211, aa246-261 or aa326-354, which peptide has an immunity-inducing activity. These peptides are useful for therapy and/or prevention of cancers when administered to a living body, and are useful for inducing T cells which exert cytotoxic activity against cancer cells when used to stimulate the T cells in vitro. | 2009-08-27 |
20090214481 | TREATMENT OF ISCHEMIA USING STEM CELLS - The invention features a method for treating or preventing ischemia in a mammal by administering unrestricted somatic stem cells (USSCs) to the mammal. | 2009-08-27 |
20090214482 | Transgenic Mammals Expressing Human Preproinsulin - Transgenic mammals which express human preproinsulin, methods and reagents for producing the transgenic mammals, and therapeutic methods of providing patients with insulin and C-peptide using tissues and cells from the transgenic mammals. | 2009-08-27 |
20090214483 | Progenitor Cells and Uses Thereof - Methods for preparing progenitor cells are described where epithelial cells are induced to undergo epithelial-mesenchymal transition as a result of exposure to an inducing agent or introduction of a gene therein that induces epithelial-mesenchymal transition. Progenitor cells resulting therefrom have use in cell-based therapies, among other utilities. | 2009-08-27 |
20090214484 | STEM CELL THERAPY FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS - The invention provides a method for treating CNS disorders by administering a neural stem cell composition and a mesenchymal stem cell composition on opposing sides of the blood brain barrier. The neural stem cell composition is administered to the central nervous system, while the mesenchymal stem cell composition is administered to the circulatory system, such as by intravenous injection. The method finds use in the treatment of degenerative GNS disorders, as well as traumatic CNS disorders such as stroke and spinal cord injury. | 2009-08-27 |
20090214485 | STEM CELL THERAPY FOR THE TREATMENT OF DIABETIC RETINOPATHY AND DIABETIC OPTIC NEUROPATHY - The invention comprises methods and stem cell compositions for the treatment of diabetic retinopathy and other degenerative diseases of the eye. The invention is practiced in two stages with the first stage comprising the administration of neural stem cells to the eye, and the second stage comprising the administration of mesenchymal cells intravenously. | 2009-08-27 |
20090214486 | Serum Response Factor and Myocardin Control Alzheimer Cerebral Amyloid Angiopathy - Cerebral amyloid angiopathy is involved in Alzheimer dementia through reduction in arterial blood flow that may impair protein synthesis, which is required for learning and memory, and lower the threshold for ischemic injury. Elevated serum response factor (SRF) or myocardin (MYOCD) activity in subjects afflicted by or at risk for development of Alzheimer's disease (AD) promotes a “vascular smooth muscle cell” (VSMC) hypercontractile phenotype in brain arteries and enhance accumulation of Aβ in the vessel wall. This, in turn, can initiate a disease process in cerebral arteries which can cause brain arterial hypoperfusion and neurovascular uncoupling, that are commonly seen in AD. Thus, SRF and MYOCD represent novel targets for treating arterial dysfunction associated with cognitive decline in AD. | 2009-08-27 |
20090214487 | USE OF MESENCHYMAL STEM CELLS FOR TREATING GENETIC DISEASES AND DISORDERS - A method of treating a genetic disease or disorder such as, for example, cystic fibrosis, Wilson's disease, amyotrophic lateral sclerosis, or polycystic kidney disease, in an animal comprising administering to said animal mesenchymal stem cells in an amount effective to treat the genetic disease or disorder in the animal. | 2009-08-27 |
20090214488 | METHODS AND COMPOSITIONS FOR TREATING BASEMENT MEMBRANE DISORDERS - The invention features methods and compositions for the treatment of basement membrane diseases and disorders, such as Alport's syndrome. | 2009-08-27 |
20090214489 | PEPTIDES AND COMPOUNDS THAT BIND TO A RECEPTOR - Described are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide mimetics. | 2009-08-27 |
20090214490 | HUMAN EMBRYONIC STEM CELL METHODS AND PODXL EXPRESSION - A method of identifying an undifferentiated human embryonic stem cell in a sample which may contain such cells, the method comprising identifying the cell or cells within the sample that express podocalyxin-like protein (PODXL) on their surface. A method of isolating an undifferentiated human embryonic stem cell from a sample containing such cells, the method comprising isolating the cell or cells within the sample that express PODXL on their surface. Typically, the methods use an antibody which binds to PODXL. Undifferentiated human embryonic stem cells isolated by the method may be useful in cell therapy. Also, in particular, compositions of cells differentiated from a human embryonic stem cell but which composition has been depleted of undifferentiated human embryonic stem cells are provided which are useful in cell therapy. | 2009-08-27 |
20090214491 | Method Of Using Mitotically Inactivated Stem Cells For Damaged Tissue Repair - The present invention is directed to the use of mitotically and/or lethally inactivated stem cells for the repair of damaged organs and/or tissues. Stem cells are mitotically and/or lethally inactivated and transplanted into damaged tissue. Any form of ex vivo inactivation of stem cells may be used such that the stem cells cannot undergo mitosis or cell division before in vivo application. Mitotically and/or lethally inactivated stem may be used to ameliorate numerous disease, injury, traumatic, ischemic, aging, and/or degenerative conditions in different types of organs and/or tissues. | 2009-08-27 |